Personal Data Protection in Clinical Research and Medical Trials in Turkey

Introduction

Personal data protection in clinical research and medical trials in Turkey is one of the most sensitive areas of healthcare, pharmaceutical, biotechnology, medical device, academic, and life sciences compliance. Clinical research is data-intensive by nature. It involves the collection, recording, analysis, transfer, monitoring, auditing, and archiving of information about volunteers, patients, healthy participants, investigators, healthcare professionals, study personnel, adverse events, laboratory results, medical history, genetic or biological samples, imaging records, and treatment outcomes.

In Turkey, clinical research is regulated by a combination of healthcare legislation, clinical trial rules, ethics committee requirements, Ministry of Health and Turkish Medicines and Medical Devices Agency procedures, international good clinical practice principles, and Law No. 6698 on the Protection of Personal Data, commonly known as KVKK. KVKK applies to personal data processed wholly or partly by automated means or by non-automated means forming part of a data filing system, and its purpose is to protect fundamental rights and freedoms, especially the right to privacy.

Clinical trials are particularly sensitive because they often involve health data, which is a special category of personal data under KVKK. They may also involve genetic data, biometric data, pregnancy data, disability information, psychiatric records, laboratory values, adverse event reports, and information about vulnerable participants. Therefore, sponsors, contract research organizations, investigators, trial sites, ethics committees, laboratories, hospitals, academic institutions, data management vendors, and pharmacovigilance teams must treat privacy compliance as an integral part of trial governance.

Clinical Research Framework in Turkey

The Turkish Medicines and Medical Devices Agency describes clinical research as research conducted with volunteers to obtain medical information, including research on human medicinal products, bioavailability studies, and bioequivalence studies. The Agency also explains that clinical research may be conducted not only for new treatments or products but also to obtain more information about known treatment methods or to find more effective uses of existing products.

Under the Turkish clinical research framework, clinical trials are conducted under the leadership of a principal investigator and by a team with sufficient training and experience appropriate to the nature of the research. The Agency’s clinical research page also states that volunteers may participate through the written consent of themselves or their legal representatives, and that clinical trials are conducted with the approval of ethics committees authorized by the Agency and the permission of the Ministry of Health.

The current medicinal product clinical trial framework is based on the Regulation on Clinical Trials of Medicinal Products for Human Use, published in the Official Gazette dated 27 May 2023 and numbered 32203. The Regulation’s purpose is to regulate the procedures and principles for conducting clinical trials involving human medicinal products and protecting volunteers’ rights, within the framework of international agreements, European Union standards, and good clinical practice.

From a data protection perspective, this framework means that clinical research compliance cannot be separated from privacy compliance. Ethics approval, informed consent, protocol design, study documentation, adverse event reporting, monitoring, archiving, and publication must all be assessed together with KVKK requirements.

Why Clinical Trial Data Is High-Risk Personal Data

Clinical trial data is high-risk because it may reveal the most intimate aspects of a participant’s life. A trial file may include diagnosis, symptoms, medication history, medical procedures, laboratory values, imaging results, genetic findings, pregnancy status, fertility information, psychiatric treatment, disability status, infectious disease status, substance use, adverse event history, family medical history, and lifestyle information.

Even where participants are identified by codes rather than names in case report forms, the data may remain personal data if the participant can be re-identified through a key held by the investigator, trial site, sponsor, or another authorized party. Pseudonymization reduces risk but does not automatically remove data from the scope of KVKK. True anonymization requires that the person can no longer be identified through reasonably available means.

The sensitivity of clinical trial data creates several legal risks. Unauthorized disclosure may cause discrimination, stigma, employment consequences, insurance problems, family conflict, psychological harm, or reputational damage. A breach involving oncology data, genetic data, psychiatric data, reproductive health data, pediatric data, or rare disease data may be particularly serious.

Health Data and Special Categories Under KVKK

KVKK treats certain data categories as special categories of personal data. These include, among others, health data, genetic data, biometric data, data relating to criminal convictions and security measures, race, ethnic origin, political opinion, philosophical belief, religion, sect or other beliefs, appearance, association or foundation membership, trade union membership, and sexual life.

In clinical research, health data is usually central. Depending on the study, genetic data, biometric data, sexual life data, pregnancy data, psychiatric records, or disability information may also be processed. These categories require a stricter legal basis and stronger safeguards than ordinary personal data.

The 2024 amendments to KVKK changed the special category data regime under Article 6. Therefore, clinical research stakeholders should not rely on old templates or outdated consent language. Each study should be reviewed under the current Article 6 framework, taking into account the nature of the data, the role of the sponsor and investigator, the legal basis, the research protocol, the informed consent form, the ethics committee documents, and the transfer structure.

Informed Consent vs KVKK Explicit Consent

One of the most important issues in Turkish clinical research is the distinction between clinical trial informed consent and KVKK explicit consent.

Clinical trial informed consent concerns the participant’s voluntary decision to participate in the research after being informed about the purpose, procedures, risks, benefits, alternatives, insurance, compensation, withdrawal rights, and other study-related matters. The Agency’s clinical research guidance emphasizes written consent by the participant or legal representative for participation.

KVKK explicit consent, on the other hand, is a data protection concept. It must be specific, informed, and freely given for the relevant personal data processing activity. A participant’s consent to join a study does not automatically mean that every personal data processing activity is lawful under KVKK. Conversely, a KVKK consent clause cannot replace the ethical and regulatory informed consent required for trial participation.

Therefore, clinical trial documentation should separate these concepts clearly. The informed consent form may include data protection explanations, but data processing notices and consent language should be drafted with KVKK requirements in mind. The participant should understand what health data will be processed, who will process it, whether coded data will be shared, whether data will be transferred abroad, how long data will be retained, whether biological samples will be stored, and how withdrawal affects already collected data.

Data Controller and Data Processor Roles in Clinical Trials

Clinical research involves multiple parties. These may include the sponsor, principal investigator, trial site, hospital, university, contract research organization, laboratory, imaging center, data management vendor, electronic data capture provider, pharmacovigilance provider, monitor, auditor, ethics committee, public authority, and sometimes foreign parent company or global sponsor.

Under KVKK, the data controller is the person or entity determining the purposes and means of processing personal data, while the data processor processes personal data on behalf of the controller based on authorization.

In many clinical trials, the sponsor determines the overall research purpose, protocol, data fields, statistical analysis plan, trial database, monitoring structure, and reporting duties. The sponsor may therefore act as a data controller for many research-related processing activities. The investigator or trial site may also act as a data controller for medical records, patient care, source documents, and site-level regulatory obligations. A CRO may act as a data processor when it performs monitoring, data management, regulatory submissions, or pharmacovigilance services on behalf of the sponsor, but it may also have independent obligations depending on its role.

The role analysis should be documented in the clinical trial agreement, data processing agreement, sponsor-CRO agreement, site agreement, privacy notice, and data transfer documents. Ambiguity in roles may create problems when responding to participant requests, handling breaches, managing cross-border transfers, or deciding retention obligations.

Privacy Notices for Clinical Research Participants

KVKK Article 10 requires data controllers to inform data subjects at the time personal data is obtained about the identity of the controller, purposes of processing, recipients and transfer purposes, method and legal basis of collection, and rights under Article 11.

A clinical trial privacy notice should be clear and study-specific. It should not be a generic hospital privacy notice. It should explain:

Who the sponsor is.
Who the investigator and trial site are.
What categories of personal data and health data will be collected.
Why the data will be processed.
Which legal basis applies.
Whether data will be coded or pseudonymized.
Who may access the data.
Whether monitors, auditors, ethics committees, regulatory authorities, laboratories, CROs, or foreign entities may receive data.
Whether data will be transferred abroad.
How long trial data will be retained.
What happens if the participant withdraws.
How participant rights may be exercised.

In clinical research, transparency must be practical. Participants should not be expected to understand complex data flows through dense legal language. The notice should be written in plain language while remaining legally accurate.

Data Minimization and Protocol Design

KVKK requires personal data to be relevant, limited, and proportionate to the processing purpose. This principle should influence protocol design.

The study should collect only data necessary for scientific objectives, safety monitoring, regulatory compliance, and statistical analysis. If a trial does not need exact home addresses, full identity numbers, or unrelated medical history, those fields should not be collected in the research database. If age range is sufficient, full date of birth may not be necessary in the sponsor database. If coded subject numbers are enough, direct identifiers should remain at the site.

Data minimization also applies to screening. Screen failure logs, pre-screening records, and recruitment lists can create privacy risk. Potential participants who are screened but not enrolled should not have their data retained indefinitely unless there is a legal, ethical, or scientific reason.

Protocol teams should involve privacy counsel early. It is easier to design a privacy-compliant trial at the beginning than to repair excessive data collection after ethics approval and database build.

Pseudonymization, Coding, and Anonymization

Clinical trials often use subject identification codes instead of direct names in trial databases. This is a strong privacy measure, but it is usually pseudonymization rather than anonymization. If the investigator site keeps a subject identification log that links the code to the participant, the data may still be personal data.

Pseudonymized data should be protected through strict separation of the coding key, limited access, secure storage, and contractual controls. Sponsors and CROs should generally avoid receiving direct identifiers unless necessary. Trial monitors may need to verify source data at the site, but copies of direct identifiers should not be transferred unnecessarily.

Anonymization may be relevant for publication, secondary research, aggregated analysis, or post-study datasets. However, anonymization must be real. Rare disease data, small sample sizes, unusual clinical profiles, location details, or detailed genetic information may create re-identification risk even if names are removed.

Biological Samples, Genetic Data, and Biobanking

Clinical research may involve blood samples, tissue samples, DNA, RNA, biomarkers, pathology materials, genomic sequencing, pharmacogenomic testing, or biobanking. These activities raise serious data protection issues because biological samples may generate genetic data and long-term identifiable research information.

Genetic data is a special category of personal data under KVKK. If biological samples are stored for future research, the participant must be informed clearly. The documentation should explain whether samples will be destroyed after the study, stored for future use, transferred abroad, coded, anonymized, used for genetic testing, or shared with third-party laboratories.

Broad future research language should be drafted carefully. Participants should understand the scope of future use as much as possible. If future use cannot be clearly defined, the sponsor should consider whether additional consent, ethics approval, or re-contact procedures may be required.

Vulnerable Participants and Pediatric Trials

Clinical trials may involve children, persons under guardianship, unconscious patients, emergency patients, elderly persons, psychiatric patients, or persons who may be economically or medically vulnerable. Data protection safeguards should be stronger in these cases.

For pediatric trials, parent or legal representative consent may be necessary for participation, and the child’s own understanding should be respected according to age and maturity. Pediatric data may include growth parameters, developmental assessments, vaccination records, genetic information, school-related information, family history, and long-term follow-up data.

The Turkish Medicines and Medical Devices Agency lists guidance on ethical approaches in clinical research conducted in pediatric populations among its clinical research guidance materials. This reinforces the need to approach pediatric research not only as a scientific matter but also as a child rights and privacy matter.

Ethics Committee and Regulatory Submission Files

Clinical research applications to ethics committees and the Agency may include the protocol, investigator brochure, informed consent form, insurance documents, investigator CVs, site information, budget documents, recruitment materials, and other study documents. The Agency states that clinical trials are conducted with ethics committee approval and Ministry permission, and that ethics committees are independent committees formed to provide scientific and ethical opinions for protecting volunteers’ rights, safety, and well-being.

These submission files may include personal data of investigators, study staff, participants in sample forms, and sometimes patient-related data. Sponsors and applicants should ensure that submission documents do not include unnecessary direct identifiers. Investigator and site personnel data should be processed with proper notices and legal bases.

The 2025 amendment to the clinical trial regulation changed the rule concerning notification of research team information before assignment: investigator information is notified to the ethics committee and the Agency, while auxiliary clinical research personnel information is notified to the ethics committee and also to the Agency if requested. This shows that even study team data must be managed as part of regulatory compliance.

Monitoring, Auditing, and Source Data Verification

Monitoring and auditing are essential for good clinical practice. Monitors may review source documents, medical records, consent forms, lab reports, adverse event files, and case report forms to verify accuracy and participant safety. However, monitoring access must still respect data minimization and confidentiality.

Monitors should access only the records necessary for the trial. Site staff should avoid exposing unrelated patient files. Direct identifiers should not be copied into sponsor systems unless necessary. Monitoring reports should avoid unnecessary participant identifiers and should use subject codes where possible.

Audit trails in electronic systems must also be protected. They may reveal who entered data, when changes were made, which participant record was reviewed, and what corrections occurred. These logs should be secure, retained appropriately, and accessed only by authorized persons.

Adverse Event Reporting and Pharmacovigilance

Clinical trials require safety reporting. Adverse event and serious adverse event reports may include health data, medical history, concomitant medication, laboratory values, hospitalization details, pregnancy information, death information, and investigator assessments.

Safety reporting may require data transfers to sponsors, CROs, pharmacovigilance teams, ethics committees, regulatory authorities, and sometimes global safety databases. The legal basis for this processing may include regulatory obligations, protection of life and health, scientific and medical safety monitoring, and establishment or protection of rights, depending on the case.

Even where safety reporting is legally necessary, reports should be limited to required information. Direct identifiers should be avoided where coded reporting is sufficient. Access to safety databases should be role-based and logged.

Cross-Border Transfers in International Clinical Trials

Many clinical trials conducted in Turkey are part of global studies. Data may be transferred to foreign sponsors, global CROs, central laboratories, electronic data capture providers, pharmacovigilance databases, data management centers, biostatistics teams, imaging review centers, or cloud platforms outside Turkey.

KVKK Article 9 was amended by Law No. 7499. The Turkish Authority announced the translation of the By-Law on transfers abroad and standard contract texts in August 2024, explaining that Article 9 had been amended and that the transfer framework includes new mechanisms.

Under the amended Article 9, transfers abroad may be based on adequacy decisions or appropriate safeguards such as standard contracts, binding corporate rules, or written commitments approved by the Board, depending on the transfer structure. Standard contracts must be notified to the Authority within five business days after signature.

Clinical trial sponsors should therefore map all international data flows before study start. The transfer map should identify data categories, recipient entities, countries, roles, transfer purposes, standard contract modules, sub-processors, onward transfers, and security measures. This is especially important where genetic data, biological sample data, imaging data, or rare disease data is transferred.

Data Security in Clinical Research

KVKK Article 12 requires data controllers to take all necessary technical and organizational measures to provide an appropriate level of security, prevent unlawful processing, prevent unlawful access, and ensure protection of personal data. Where data is processed by another person on behalf of the controller, the controller is jointly responsible with that person for security measures.

Clinical research security measures should include:

Role-based access to trial databases.
Multi-factor authentication for electronic data capture systems.
Encryption in transit and at rest.
Secure coding key storage at sites.
Restricted access to source documents.
Secure remote monitoring procedures.
Confidentiality undertakings for study staff.
Vendor due diligence for CROs and laboratories.
Audit logs for data entry and access.
Secure transfer channels for medical images and lab results.
Incident response procedures.
Regular access review.
Secure archiving and destruction.

Clinical trial data should not be stored in uncontrolled spreadsheets, personal email accounts, messaging applications, unsecured cloud folders, or personal devices. Remote monitoring and decentralized trial tools should receive special scrutiny because they may expand access to participant data.

Retention and Archiving of Clinical Trial Data

Clinical research requires long-term archiving for regulatory, scientific, inspection, safety, and legal reasons. The Turkish Medicines and Medical Devices Agency lists a Clinical Trials Archiving Principles Guide among its clinical research materials and states that organizations wishing to provide archiving services for clinical research documents require permission from the Agency.

From a KVKK perspective, retention must be based on law, regulatory obligations, scientific necessity, legal defense, or another valid purpose. Once the reasons requiring processing no longer exist, personal data must be erased, destroyed, or anonymized under KVKK Article 7.

A clinical trial retention policy should distinguish between source documents, investigator site files, trial master files, informed consent forms, screening logs, subject identification logs, safety reports, monitoring reports, laboratory records, biological samples, electronic databases, backups, and publication datasets.

Where data must be retained for regulatory inspection, access should remain restricted. Long retention does not justify broad access or uncontrolled storage.

Data Subject Rights in Clinical Research

Participants have rights under KVKK Article 11, including the right to learn whether personal data is processed, request information, learn processing purposes, know domestic and foreign transfer recipients, request correction, request erasure or destruction under legal conditions, object to adverse automated results, and claim compensation for unlawful processing.

In clinical trials, these rights must be managed carefully because research data may be subject to regulatory retention, scientific integrity requirements, safety reporting duties, and source document obligations. A participant may withdraw from the study, but already collected data may still need to be retained or used for safety, regulatory, or scientific validity reasons where legally justified.

The privacy notice and informed consent documents should explain this clearly. Participants should know how to contact the investigator site or sponsor for data protection requests and how withdrawal affects data already collected.

Data Breach Risks in Clinical Trials

Clinical trial breaches may involve lost study laptops, misdirected lab reports, exposed EDC credentials, unauthorized access to medical records, ransomware at a hospital, leakage of genetic data, insecure transfer of medical images, or accidental disclosure of participant lists.

Because clinical trial data often includes special category health data, breach consequences may be serious. Sponsors and sites should have a written breach response plan. The plan should define who investigates the incident, who informs the sponsor, who contacts the CRO or vendor, who assesses KVKK notification duties, who informs participants where required, and how the risk will be mitigated.

Contracts between sponsors, CROs, sites, and vendors should contain rapid breach notification clauses. A CRO or vendor should not wait until a complete forensic report is ready before notifying the sponsor of a suspected incident.

Practical KVKK Compliance Checklist for Clinical Research in Turkey

Sponsors, CROs, investigators, and trial sites should:

1. Map all participant, investigator, staff, and vendor data flows.
2. Identify controller and processor roles for sponsor, site, CRO, lab, and vendors.
3. Separate clinical informed consent from KVKK data protection consent and notice language.
4. Prepare study-specific privacy notices.
5. Identify legal bases under KVKK Articles 5 and 6.
6. Apply special safeguards to health, genetic, biometric, and pediatric data.
7. Minimize direct identifiers in sponsor databases.
8. Use coding and pseudonymization wherever possible.
9. Protect subject identification logs at trial sites.
10. Limit monitoring access to necessary source documents.
11. Control safety reporting data flows.
12. Assess future use of biological samples and genetic data.
13. Map cross-border transfers before trial start.
14. Use Article 9 safeguards, including standard contracts where required.
15. Notify standard contracts within five business days after signature where applicable.
16. Implement technical and organizational security measures.
17. Sign data processing agreements with CROs and vendors.
18. Define archiving and retention periods.
19. Establish participant rights request procedures.
20. Prepare data breach response workflows.

Common Mistakes in Clinical Research Data Protection

One common mistake is assuming that clinical informed consent automatically covers all KVKK requirements. Another is using generic hospital privacy notices instead of study-specific disclosures. A third mistake is transferring coded trial data abroad without Article 9 analysis.

Other frequent mistakes include collecting excessive identifiers, giving sponsors unnecessary access to direct patient records, using unsecured email for lab reports, failing to regulate CRO and vendor roles, keeping screening data indefinitely, treating pseudonymized data as anonymous, and failing to explain what happens to data after withdrawal.

Clinical trial stakeholders also sometimes overlook investigator and study personnel data. CVs, training certificates, financial disclosures, delegation logs, and conflict of interest declarations are also personal data and should be processed lawfully.

Conclusion

Personal data protection in clinical research and medical trials in Turkey requires a careful combination of KVKK compliance, clinical trial regulation, ethics committee requirements, good clinical practice, participant rights, and scientific integrity. Clinical research cannot function without data, but that data often includes highly sensitive health, genetic, biometric, pediatric, and adverse event information.

The strongest compliance model begins at protocol design. Sponsors and investigators should collect only necessary data, use coding and pseudonymization, provide study-specific privacy notices, separate informed consent from data protection consent concepts, define legal bases, secure study systems, control vendor access, map cross-border transfers, and establish retention and breach response procedures.

Turkey’s clinical trial framework requires ethics committee approval and Ministry permission for clinical trials, while KVKK imposes independent obligations regarding lawful processing, transparency, data security, transfers, retention, and data subject rights.

For sponsors, CROs, hospitals, universities, investigators, laboratories, and medical research vendors, personal data protection is not an administrative formality. It is a central part of protecting volunteers’ rights, ensuring trust in research, preserving scientific credibility, and reducing legal risk in Turkey’s clinical research environment.